pathway_name,pathway_id,pathway_url,gene_symbol,ensg_id,chembl_id,drug_name,phase,status,disease_id,disease_name,mechanismOfAction,smiles
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
